šŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Ono Pharmaceutical Co., Ltd. (TYO:4528)
Japan flag Japan Ā· Delayed Price Ā· Currency is JPY
2,489.00
-3.00 (-0.12%)
Nov 18, 2026, 3:30 PM JST
← View all transcripts

Jefferies Global Healthcare Conference

Nov 16, 2026

Summary

FY2026 forecasts are JPY 455bn revenue and JPY 124bn core operating profit, while overseas product sales are expected to exceed half by FY2035. Global launches and Phase III programs are intended to broaden growth beyond OPDIVO.

Steve Barker
Healthcare Analyst, Jefferies

Thanks, everyone, for joining. My name is Steve Barker, a healthcare analyst for Jefferies in Japan, and it is my pleasure to introduce Ono Pharmaceutical. We have the President and COO, Mr. Takino. Takino-san, I think you have some slides, so over to you.

Toichi Takino
President and COO, Ono Pharmaceutical

Can you hear me? Good afternoon, everyone. I am Toichi Takino, President and COO of Ono Pharma. I am happy to come back to this lovely London and lovely Jefferies conference. Thank you, Stephen . Today, I would like to share that we are at a very exciting moment, transferring into such a company to continue delivering breakthrough medicines to worldwide patients. This is First, I will cover our history, our business today, and our products driving global expansion. Ono has been always dedicated to the fight against disease and pain, continually taking on new challenges in innovation for more than 300 years. We launched the first in the world prostaglandin products in the 1970s to 1990s, and also the first in the world anti-PD-1 antibody, OPDIVO, a decade ago. After that, in 2024, we acquired Deciphera to gear up acceleration of our transformation.

Where we stand today, let me share our financial outlook for ongoing fiscal 2026. We expect a revenue of JPY 455 billion and core OP of JPY 124 billion, representing a core OP margin around 30%. Growth in QINLOCK and ROMVIMZA, together with increased royalty income, is pushing up the share of global revenue, and our business remains on a solid foundation. At the same time, we plan to invest JPY 143 billion in R&D this fiscal year, as we have already initiated three global phase III studies this year. We will continue investing in R&D for our future growth. In acquiring Deciphera, we had three objectives. First, to reinforce our global product expansion by acquiring QINLOCK and ROMVIMZA, and now both products are steadily growing.

Second, to establish our global business platform by acquiring experienced development and commercial team in U.S. and Europe, and now it is fully leveraged to advance our assets from Japan toward launch in the U.S. and Europe. Third, to combine Deciphera's kinase drug discovery expertise with Ono's research capabilities, and now beyond just the discovery, the acquisition played a significant role in global license to sapablursen. Next, let me briefly update our global products. These are the first three products driving our global expansion: QINLOCK, ROMVIMZA, and tirabrutinib. We acquired QINLOCK in 2024 and launched ROMVIMZA in 2025. This year, 2026, if tirabrutinib is approved in U.S., it will become our third global product in three consecutive years, in good shape.

The proportion of overseas product sales is expected to increase from 3% before the acquisition to 16% in fiscal 2026, and finally to be more than half by fiscal 2035, definitely. Beyond just generating global revenue, these three products are also enabling us to build our capabilities to successfully bring our future products in the U.S. and Europe. Let me give you a little more details respectively. QINLOCK is a selective oral KIT inhibitor for the treatment of gastrointestinal stromal tumor, or GIST, a rare sarcoma. It is already established its strong position after three TKI therapy, and already approved in more than 40 countries. The quarterly sales trend shown here demonstrate very consistent growth, and we expect its sales of JPY 43 billion this fiscal year. To further grow with phase III INSIGHT study data expected soon for second-line patients with specific genetic mutations.

Second product, ROMVIMZA, selective CSF1R inhibitor for tenosynovial giant cell tumor, or TGCT, another very burdensome rare benign sarcoma in the joints. After approved in both U.S. and Europe last year, we expect its sales of JPY 19 billion this fiscal year. Prescription by medical oncologists and geographical markets are steadily expanding, but disease awareness, patient diagnosis, and referral paths from orthopedic surgeons are all important for our further market cultivation. Next, tirabrutinib is our selective BTK inhibitor for the treatment of primary CNS lymphoma, or PCNSL, a rare cancer accounting for 2%-4% of brain tumors. It has been already marketed in Japan, but not yet in U.S., so there is no currently approved therapy for PCNSL. PCNSL has both nature of hematologic and CNS malignancy. Therefore, it is expected to create our future foothold in hematology for sapablursen and in neurology for ONO-2808.

The PDUFA date is about in a month, December 18. Here, I briefly touch on four assets for Asian market in rather near term. We are expanding our business globally, but Asia, especially Japan market, remains important for us, where we continue to launch new product as shown here. XCOPRI, it is sodium GABA dual channel modulator for epilepsy partial onset seizures from SK, and just launched in Japan last Friday under the famous major Microsoft outage. Other three assets are all phase III stages. Povetacicept is APRIL/BAFF dual inhibitor antibody for IgAN or IgA nephropathy from Vertex. GEL-ONE is cross-linked hyaluronate for osteoarthritis from Seikagaku. BHV-1300, a novel IgG degrader for Graves' disease, which is also a very promising program and just partnered from Biohaven last month.

Primary completion of ongoing phase III studies for these three assets are expected in fiscal 2027, so that their revenue contribution is expected by 2030. Now, I would like to turn to the progress of our promising pipeline. Our focus is three therapeutic area: oncology, neurology, immunology, inflammation. Out of them, QINLOCK, ROMVIMZA, and tirabrutinib represent our first wave of global product, as I said, already launched or launching stage. The next wave, sapablursen, ONO-4578, and ONO-2808 have all advanced into global phase III stage, and further followed by new programs such as ONO-1110 and ONO-2020 from their proof of concept stage. Actually, our latest positive news was about the ONO-1110, an endogenous cannabinoid modulator that successfully demonstrated promising efficacy signals across three pain indications. I'll come back later. So this summarizes our pipeline by its development stage.

You may see our pipeline is definitely getting enriched and promising with a variety of brand-new mode of actions. Among these, I want to feature four programs for their updates. First, ONO-4578 EP4 antagonist is to enhance the effect of immune checkpoint inhibitor, as presented with its phase II data in ASCO 2026. In our global phase III study in gastric cancer, ONO-4578 is evaluated in combination with nivolumab and chemotherapy. Here summarized study design of phase III study for HER2-negative and PD-L1-positive first-line gastric cancer. Primary completion is expected in January 2031, and we will strive to deliver this treatment option to the patients as quickly as possible. With our GIST network through QINLOCK, and also with our immune oncology deep know-how through OPDIVO, we aim to expand our presence in gastrointestinal cancers with ONO-4578.

Second, ONO-2808 is an S1P5 agonist for multiple system atrophy, or MSA, a life-threatening progressive neurodegenerative disease with no treatment available and with life expectancy after diagnosis just less than 10 years. As presented in World Parkinson Congress 2026, we confirmed positive signals in its phase II study to slow down disease progression in both clinical symptom as well as MRI-based volumetric brain shrinkage. It is particularly impressive to have these two independent assessments pointed in the same direction. Our phase III study focuses on parkinsonian MSA, or MSA-P, the predominant subtype in Western countries, and its primary endpoint is modified UMSARS, the global standard symptom scale for MSA. Its primary completion is expected in 2029, but we are committed to bringing this potential breakthrough to MSA patients as quickly as possible. The third, sapablursen phase III program, a TMPRSS6-targeting antisense for polycythemia vera from Ionis.

Also as presented in ASH 2025, with its phase II data with once-monthly subcutaneous injection, sapablursen is expected to reduce the severe burden of phlebotomy while maintaining appropriate hematocrit control. The program has received Fast Track and Breakthrough Therapy designation in U.S., as well as orphan drug designation in U.S., Europe, and Japan. We expect our synergetic and efficient business foundation in hematology through tirabrutinib and this sapablursen. Before moving to the fourth program, ONO-1110, let me briefly share our historical records in neuroscience field. You may consider Ono just OPDIVO company, but the reality is, Ono has been dedicated in neuroscience as well, across Alzheimer's, Parkinson's, epilepsy, cerebrovascular disease, and pain management through its R&D to representative products for almost half century long.

Therefore, our recent successful progress of series of first-in-class CNS programs like ONO-2808, ONO-1110, and hopefully ONO-2020 as well, are definitely not by chance or not by a fluke, but from our solid expertise and dedication in neuroscience, together with recent advancement of science and technology. Now finally back in our oral endocannabinoid modulator, ONO-1110. As mentioned earlier, we recently announced its promising efficacy signal demonstrated across three pain indications. By modulating new endogenous cannabinoid system naturally equipped in our body, we believe it has the potential to provide pain relief without unfavorable side effects often associated with exogenous cannabinoids or any other painkillers. We cannot share data until due presentation at some scientific conference, but we can say that we confirmed its proof of concept in PHN or post-herpetic neuralgia, or IC or interstitial cystitis.

Therefore, for PHN, we move forward to global phase II-B dose response study, along with one more phase II study in parallel in another neuropathic pain in Japan, aiming at comprehensive peripheral neuropathic pain indication. For IC, we are moving to global phase II study for IC and BPS, or bladder pain syndrome. For fibromyalgia, as we identified a patient population most likely to benefit, we are going to see whether we can reproduce positive signal in another phase II study in Japan. As you can see, ONO-1110 has the potential to become a highly valuable treatment option in pain management field. With these products and pipeline progress in mind, let's move to our future outlook. We will continue delivering multiple specialty medicines to global markets while expanding our focus from current sarcoma field into gastrointestinal cancers, hematologies, and neurology.

From sarcoma and GIST with QINLOCK and ROMVIMZA, we will extend our business domain to gastrointestinal cancers through ONO-4578. In hematology, we will continue building our expertise around tirabrutinib and sapablursen. In neurology, we will relay our CNS presence with tirabrutinib toward ONO-2808 in MSA and ONO-1110 in pain. This is my last slide, but through my presentation today, I hope now you can see how exciting transformative phase Ono is standing right now, and actually it is due moving ahead. OPDIVO IV will face patent expiry in U.S. in 2028, Europe in 2030, and Japan in 2031. However, we expect the transition to the subcutaneous form to turn that impact to more gradual slope, and the launches of AGM assets are to push up our revenue in near term.

But our target is not simply about mitigating the loss of exclusivity of OPDIVO IV, but further growth beyond OPDIVO. We are relaying our first three global products, QINLOCK, ROMVIMZA, tirabrutinib , to our next three global products, sapablursen, ONO-4578, and 2808. And beyond these, we will further continue to create multiple growth drivers like 1110 and ONO-2020. Talking a little bit about ONO-2020, our brand new epigenetic modulator, currently under our data review or analysis of just finished phase II proof of concept study for Alzheimer disease. It is expected to be announced by the end of this year, and please stay tuned. Innovation in our pharma industry takes really a long time and large investment. However, we will not stop our investment in the growth opportunity in our hands. That will shape our future and will help patients and their families around the world.

Once again, let me reiterate that we are now at the very much exciting moment in our transformation, and it is already underway. Through our product growth and pipeline progress, we will for sure demonstrate our transformation step by step, which you won't want to miss. We welcome you. Join us on our exciting journey with long-term perspective. Thank you very much for your attention. Thank you.

Steve Barker
Healthcare Analyst, Jefferies

Thanks very much, Takino-san. I think we're just about out of time, but congratulations on transforming the company into.

Toichi Takino
President and COO, Ono Pharmaceutical

Thank you.

Steve Barker
Healthcare Analyst, Jefferies

An international company in a short period of time. Where's the gap between where Ono is now and where investors are thinking about your company?

Toichi Takino
President and COO, Ono Pharmaceutical

Actually, as you probably noticed from my sound, we are very much confident about our upcoming very promising pipelines. Because of its sort of two brand new approaches, new mode of action, their assessment is still under evaluated. But definitely, because we are the person who already reviewed the data, our confidence is strong enough. Therefore, we hope the market assessment going to catch up soon. Therefore, it could be a good time for you to join us before the market response. That's my only words.

Steve Barker
Healthcare Analyst, Jefferies

Thanks, Takino-san.

Toichi Takino
President and COO, Ono Pharmaceutical

Thank you so much.